Prediction of adeno-associated virus neutralizing antibody activity for clinical application

Gene Therapy

Volumn 22, Issue 12, 2015, Pages 984-992

  Wang, M ^a,b   Crosby, A ^b   Hastie, E ^b   Samulski, J J ^c   McPhee, S ^c   Joshua, G ^b   Samulski, R J ^b   Li, C ^b  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c ASKLEPIOS BIOPHARMACEUTICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CELL COUNT; CELL DENSITY; CLINICAL STUDY; CONTROLLED STUDY; GENE THERAPY; HINDLIMB MUSCLE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TEMPERATURE; MOUSE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA VOLUME; PREDICTION; PRIORITY JOURNAL; SEROTYPE; TRANSGENE; ANIMAL; BLOOD; C57BL MOUSE; DEPENDOPARVOVIRUS; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; IMMUNOLOGY; PROCEDURES;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HELA CELLS; HUMANS; MICE; MICE, INBRED C57BL; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84949089637     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.69     Document Type: Article

References (46)

1. Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012; 4: 120ra15.
2. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009; 374: 1597-1605.
3. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr., Mingozzi F, Bennicelli J et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-2248.
4. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
5. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994-2004.
6. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-2365.
7. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010; 18: 643-650.
8. Testa F, Maguire AM, Rossi S, Pierce EA, Melillo P, Marshall K et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 2013; 120: 1283-1291.
9. Blacklow NR, Hoggan MD, Kapikian AZ, Austin JB, Rowe WP. Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol 1968; 88: 368-378.
10. Blacklow NR, Hoggan MD, Rowe WP. Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst 1968; 40: 319-327.
11. Georg-Fries B, Biederlack S, Wolf J, zur Hausen H. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology 1984; 134: 64-71.
12. Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999; 73: 3994-4003.
13. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 2000; 74: 1761-1766.
14. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59: 406-411.
15. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy 1999; 6: 1574-1583.
16. Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 2000; 74: 1524-1532.
17. Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 2006; 107: 1810-1817.
18. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009; 199: 381-390.
19. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Therapy 2010; 21: 704-712.
20. Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Therapy 2012; 19: 288-294.
21. Liu Q, Huang W, Zhang H, Wang Y, Zhao J, Song A et al. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Therapy 2014; 21: 732-738.
22. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2012; 20: 443-455.
23. Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adenoassociated virus antibodies as a challenge in AAV gene therapy. Hum Gene Therapy Methods 2013; 24: 59-67.
24. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K et al. Recombinant adenoassociated virus for muscle directed gene therapy. Nat Med 1997; 3: 306-312.
25. Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 1997; 71: 5932-5941.
26. Manning WC, Zhou S, Bland MP, Escobedo JA, Dwarki V. Transient immunosuppression allows transgene expression following readministration of adenoassociated viral vectors. Hum Gene Therapy 1998; 9: 477-485.
27. Halbert CL, Standaert TA, Wilson CB, Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol 1998; 72: 9795-9805.
28. Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR. Latent adenoassociated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol 1999; 73: 8549-8558.
29. Beck SE, Jones LA, Chesnut K, Walsh SM, Reynolds TC, Carter BJ et al. Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol 1999; 73: 9446-9455.
30. Chao H, Samulski R, Bellinger D, Monahan P, Nichols T, Walsh C. Persistent expression of canine factor IX in hemophilia B canines. Gene Therapy 1999; 6: 1695-1704.
31. Cottard V, Mulleman D, Bouille P, Mezzina M, Boissier MC, Bessis N. Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Therapy 2000; 7: 1930-1939.
32. Chirmule N, Xiao W, Truneh A, Schnell MA, Hughes JV, Zoltick P et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000; 74: 2420-2425.
33. Anand V, Chirmule N, Fersh M, Maguire AM, Bennett J. Additional transduction events after subretinal readministration of recombinant adeno-associated virus. Hum Gene Therapy 2000; 11: 449-457.
34. Nathwani AC, Davidoff A, Hanawa H, Zhou JF, Vanin EF, Nienhuis AW. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 2001; 97: 1258-1265.
35. Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Therapy 2002; 13: 1349-1359.
36. Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Buning H et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Therapy 2003; 10: 2139-2147.
37. Peden CS, Burger C, Muzyczka N, Mandel RJ. Circulating anti-wild-type adenoassociated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 2004; 78: 6344-6359.
38. Le HT, Yu QC, Wilson JM, Croyle MA. Utility of PEGylated recombinant adeno-associated viruses for gene transfer. J Control Release 2005; 108: 161-177.
39. Halbert CL, Miller AD, McNamara S, Emerson J, Gibson RL, Ramsey B et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Therapy 2006; 17: 440-447.
40. Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 2006; 108: 3321-3328.
41. Li C, Diprimio N, Bowles DE, Hirsch ML, Monahan PE, Asokan A et al. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol 2012; 86: 7752-7759.
42. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006; 14: 316-327.
43. Weinberg MS, Nicolson S, Bhatt AP, McLendon M, Li C, Samulski RJ. Recombinant adeno-associated virus utilizes cell-specific infectious entry mechanisms. J Virol 2014; 88: 12472-12484.
44. Sun L, Tu L, Gao G, Sun X, Duan J, Lu Y. Assessment of a passive immunity mouse model to quantitatively analyze the impact of neutralizing antibodies on adeno-associated virus-mediated gene transfer. J Immunol Methods 2013; 387: 114-120.
45. Denard J, Beley C, Kotin R, Lai-Kuen R, Blot S, Leh H et al. Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J Virol 2012; 86: 6620-6631.
46. Denard J, Marolleau B, Jenny C, Rao TN, Fehling HJ, Voit T et al. C-reactive protein (CRP) is essential for efficient systemic transduction of recombinant adenoassociated virus vector 1 (rAAV-1) and rAAV-6 in mice. J Virol 2013; 87: 10784-10791.